Disease / condition
Non-small Cell Lung Cancer clinical trials
Free access to 673 studies10+ countriesUpdated daily137 recruiting
VerifiedClinicalTrials.gov · WHO ICTRP · regional registries
673
Total trials
10+
Countries
10+
Sponsors
137
Recruiting
By phase
Phase 2272
N/A166
Phase 389
Phase 163
Early Phase 146
By status
Completed199
Recruiting137
Unknown133
Not yet recruit...89
Terminated55
Top countries
China248
United States of America118
South Korea28
Japan25
Canada16
Top sponsors
Sun Yat-sen Univer...28
AstraZeneca18
Betta Pharmaceutic...14
Hunan Province Tum...13
Eli Lilly and Comp...12
Recent trials
Latest clinical trials for Non-small Cell Lung Cancer
Patient-derived Organoid Drug Sensitivity Guided Treatment for Drug-resistant Recurrent Non-Small Cell Lung Cancer
Henan Cancer Hospital · China
NCT06406608Recruiting
FMT+Immunotherapy+Chemotherapy as First-line Treatment for Driver-gene Negative Advanced NSCLC
Changzhou No.2 People's Hospit...
NCT06403111Not yet recr...
- Phase
- Phase 2
ICI Rechallenge for Advanced NSCLC With Long-Term Response to First-Line ICI
Peking Union Medical College H... · China
NCT06388031Not yet recr...
- Phase
- Phase 2
A Study Comparing BL-B01D1 With Docetaxel in Patients With Unresectable Locally Advanced or Metastatic EGFR Wild-type Non-small Cell Lung Cancer
Sichuan Baili Pharmaceutical C... · China
NCT06382129Not yet recr...
- Phase
- Phase 3
A Study Comparing BL-B01D1 With Platinum Based Chemotherapy in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer
Sichuan Baili Pharmaceutical C... · China
NCT06382116Not yet recr...
- Phase
- Phase 3
the Prevention of Bone Marrow Suppression Caused by Chemotherapy in Advanced NSCLC With Trilaciclib
Henan Cancer Hospital · China
NCT06370416Not yet recr...
- Phase
- Phase 2
Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer
AstraZeneca · Australia,China,South Korea,Taiwan
NCT06350097Not yet recr...
- Phase
- Phase 3
Survival Validation and Gene Mutations of N Descriptors in the Ninth Edition of the TNM Classification for Lung Cancer
Fudan University · China
NCT06349252Recruiting
Sunvozertinib Plus Anlotinib as 1L Treatment in EGFR Mutant Advanced NSCLC-RW
Hunan Province Tumor Hospital · China
NCT06355609Not yet recr...
- Phase
- Phase 2
A Study of MK-1084 Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant, Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004)
Merck Sharp & Dohme LLC · United States of America
NCT06345729Recruiting
- Phase
- Phase 3
To Evaluate the Safety and Tolerability of Carbognilumab Combined With Chemotherapy as the First-line Treatment for Patients With KEAP1 Mutated Advanced or Postoperative Recurrent Non-small Cell Lung Cancer (NSCLC)
Guangzhou Institute of Respira... · China
NCT06341660Recruiting
- Phase
- Phase 2
A Single-arm Pilot Study of First-line Treatment With Carbognilumab Combined With Chemotherapy in Patients With STK11-mutated Advanced or Postoperative Recurrent Non-small Cell Lung Cancer
Guangzhou Institute of Respira... · China
NCT06331650Recruiting
- Phase
- Phase 2
Anlotinib Combined With Penpulimab as Front-line Treatment in Advanced Non-small Cell Lung Cancer
The First Affiliated Hospital ... · China
NCT06341530Recruiting
- Phase
- Phase 2
Assessment of the Safety and Efficacy of Balstilimab in Combination With Botensilimab for the Treatment of Non-Small Cell Lung Cancer (IMMONC0008)
Immune Oncology Research Insti... · Armenia
NCT06322108Not yet recr...
- Phase
- Phase 2
Efficacy of Cadonilimab in Non-squamous Non-small Cell Lung Cancer Patients Resistant to EGFR-TKI
Guangzhou University of Tradit... · China
NCT06277674Recruiting
- Phase
- Phase 2
Neoadjuvant Lazertinib With or Without Chemotherapy for Patients With EGFR-mutated Resectable Non-small Cell Lung Cancer
Yonsei University · South Korea
NCT06268210Not yet recr...
- Phase
- Phase 2
A Phase II Clinical Trial of DZD9008 in Combination With AZD4205 in Standard Treatment Failed NSCLC Patients With EGFR Mutations (WU-KONG21)
Dizal Pharmaceuticals · China
NCT06295432Recruiting
- Phase
- Phase 2
DZD9008 In Combination With Bevacizumab in Locally Advanced or Metastatic NSCLC Patients With EGFR Mutation (WU-KONG29)
Dizal Pharmaceuticals · China
NCT06276283Recruiting
- Phase
- Phase 2
A Study Of SY-3505 Versus Crizotinib In First Line Treatment Of Patients With ALK-Positive NSCLC
Shouyao Holdings (Beijing) Co.... · China
NCT06254599Not yet recr...
- Phase
- Phase 3
An Observational Study on Predicting the Efficacy of Immunotherapy for NSCLC Based on LIRAscore
Nanfang Hospital, Southern Med... · China
NCT06232265Recruiting
About this profile
Access comprehensive clinical trial information for Non-small Cell Lung Cancer through Pure Global AI's free database. This collection includes 673 clinical trials across multiple phases including Phase 2, N/A, Phase 3. Currently, 137 trials are actively recruiting participants.
Research for Non-small Cell Lung Cancer is being conducted in China, United States of America, South Korea and 7+ other countries. Leading sponsors include Sun Yat-sen University and AstraZeneca. Pure Global AI offers free access to clinical trial data from ClinicalTrials.gov, WHO ICTRP, and regional registries worldwide.
Pure Global AI provides free access to 673 clinical trials studying Non-small Cell Lung Cancer, aggregated from major global registries including ClinicalTrials.gov, WHO ICTRP, and regional databases.
The trials span multiple phases, from early Phase 1 safety studies to large-scale Phase 3 efficacy trials, conducted across 10+ countries.
Top research sponsors include Sun Yat-sen University, AstraZeneca, Betta Pharmaceuticals Co., Ltd., among others.